These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2701270)

  • 1. Epidemiologic assessment of adverse drug effects.
    Stern RS
    Semin Dermatol; 1989 Sep; 8(3):136-40. PubMed ID: 2701270
    [No Abstract]   [Full Text] [Related]  

  • 2. [Physician and pharmaceutical industry. II. Postmarketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse drug reaction monitoring in pediatric practice.
    Kshirsagar NA; Karande S
    Indian Pediatr; 1996 Dec; 33(12):993-8. PubMed ID: 9141798
    [No Abstract]   [Full Text] [Related]  

  • 4. [Necessity and difficulties of quantitative drug monitoring].
    Lagier G; Dally S; Vincens M; Castot A
    Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance].
    Stricker BH; Herings RM; Bakker A; Valkenburg HA; Sturmans F
    Ned Tijdschr Geneeskd; 1990 Sep; 134(39):1886-9. PubMed ID: 2215766
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
    Lagier G; Vincens M; Lefebure B; Frelon JH
    Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
    [No Abstract]   [Full Text] [Related]  

  • 7. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S; Bryant SG; Kluge RM
    Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
    [No Abstract]   [Full Text] [Related]  

  • 8. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
    Graham DJ; Smith CR
    Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
    [No Abstract]   [Full Text] [Related]  

  • 10. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
    Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
    Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
    [No Abstract]   [Full Text] [Related]  

  • 11. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 12. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse drug reactions.
    Turner P
    Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
    [No Abstract]   [Full Text] [Related]  

  • 15. [Postmarketing surveillance of adverse reactions of drugs].
    Polli EE; Cortellaro M
    Ann Ital Med Int; 1989; 4(1):1-9. PubMed ID: 2702012
    [No Abstract]   [Full Text] [Related]  

  • 16. [Methods for studying the adverse effects of drugs. I. Comparison of imputability methods: modelling and methodology].
    Péré JC; Begaud B; Haramburu F; Albin H
    Therapie; 1984; 39(3):279-89. PubMed ID: 6463953
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of an algorithm to evaluate published reports of adverse drug reactions.
    Case B; Oszko MA
    Am J Hosp Pharm; 1991 Jan; 48(1):121-2. PubMed ID: 2000870
    [No Abstract]   [Full Text] [Related]  

  • 18. Notifying patients of adverse drug reactions.
    Pane FJ; Ringer L; Ferguson L; Koshko N
    Am J Hosp Pharm; 1991 Feb; 48(2):236-7. PubMed ID: 2003491
    [No Abstract]   [Full Text] [Related]  

  • 19. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.